Interview With Timothy Ko

In this episode of the Psychedelic Spotlight podcast, we spend some time with Timothy Ko who is the CEO of Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) (FSE: “1XU1”) a biotechnology company focused on developing psychedelic medicines to treat addiction.

In our conversation with Mr. Ko, we discuss how the company plans to utilize the psychedelic compound, DMT, to address the global addiction crisis, and how they are using genetics to develop more effective personalized treatment regimens for patients.

*To learn more about the company featured in this episode and the work they’re doing, visit their website: EntheonBiomedical.com

Have you heard about our new community?

We’re excited to announce Bonfire -
a personal growth community for people who are interested in psychedelics.

Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.

Sign Up Here